0001551152falseDecember 312022Q3http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2022#ForeignCurrencyTransactionGainLossBeforeTaxhttp://fasb.org/us-gaap/2022#ForeignCurrencyTransactionGainLossBeforeTaxhttp://fasb.org/us-gaap/2022#ForeignCurrencyTransactionGainLossBeforeTaxhttp://fasb.org/us-gaap/2022#ForeignCurrencyTransactionGainLossBeforeTaxhttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNet100015511522022-01-012022-09-300001551152exch:XCHIus-gaap:CommonStockMember2022-01-012022-09-300001551152us-gaap:CommonStockMemberexch:XNYS2022-01-012022-09-300001551152abbv:Sec1500SeniorNotesDue2023Memberexch:XNYS2022-01-012022-09-300001551152abbv:Sec1.375SeniorNotesDue2024Memberexch:XNYS2022-01-012022-09-300001551152abbv:Sec1250SeniorNotesDue2024Memberexch:XNYS2022-01-012022-09-300001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2022-01-012022-09-300001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2022-01-012022-09-300001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2022-01-012022-09-300001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2022-01-012022-09-300001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2022-01-012022-09-3000015511522022-10-26xbrli:shares00015511522022-07-012022-09-30iso4217:USD00015511522021-07-012021-09-3000015511522021-01-012021-09-30iso4217:USDxbrli:shares00015511522022-09-3000015511522021-12-310001551152us-gaap:CommonStockMember2021-06-300001551152us-gaap:TreasuryStockMember2021-06-300001551152us-gaap:AdditionalPaidInCapitalMember2021-06-300001551152us-gaap:RetainedEarningsMember2021-06-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001551152us-gaap:NoncontrollingInterestMember2021-06-3000015511522021-06-300001551152us-gaap:CommonStockMember2021-07-012021-09-300001551152us-gaap:TreasuryStockMember2021-07-012021-09-300001551152us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001551152us-gaap:RetainedEarningsMember2021-07-012021-09-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001551152us-gaap:NoncontrollingInterestMember2021-07-012021-09-300001551152us-gaap:CommonStockMember2021-09-300001551152us-gaap:TreasuryStockMember2021-09-300001551152us-gaap:AdditionalPaidInCapitalMember2021-09-300001551152us-gaap:RetainedEarningsMember2021-09-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001551152us-gaap:NoncontrollingInterestMember2021-09-3000015511522021-09-300001551152us-gaap:CommonStockMember2022-06-300001551152us-gaap:TreasuryStockMember2022-06-300001551152us-gaap:AdditionalPaidInCapitalMember2022-06-300001551152us-gaap:RetainedEarningsMember2022-06-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001551152us-gaap:NoncontrollingInterestMember2022-06-3000015511522022-06-300001551152us-gaap:CommonStockMember2022-07-012022-09-300001551152us-gaap:TreasuryStockMember2022-07-012022-09-300001551152us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001551152us-gaap:RetainedEarningsMember2022-07-012022-09-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001551152us-gaap:NoncontrollingInterestMember2022-07-012022-09-300001551152us-gaap:CommonStockMember2022-09-300001551152us-gaap:TreasuryStockMember2022-09-300001551152us-gaap:AdditionalPaidInCapitalMember2022-09-300001551152us-gaap:RetainedEarningsMember2022-09-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001551152us-gaap:NoncontrollingInterestMember2022-09-300001551152us-gaap:CommonStockMember2020-12-310001551152us-gaap:TreasuryStockMember2020-12-310001551152us-gaap:AdditionalPaidInCapitalMember2020-12-310001551152us-gaap:RetainedEarningsMember2020-12-310001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001551152us-gaap:NoncontrollingInterestMember2020-12-3100015511522020-12-310001551152us-gaap:CommonStockMember2021-01-012021-09-300001551152us-gaap:TreasuryStockMember2021-01-012021-09-300001551152us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300001551152us-gaap:RetainedEarningsMember2021-01-012021-09-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300001551152us-gaap:NoncontrollingInterestMember2021-01-012021-09-300001551152us-gaap:CommonStockMember2021-12-310001551152us-gaap:TreasuryStockMember2021-12-310001551152us-gaap:AdditionalPaidInCapitalMember2021-12-310001551152us-gaap:RetainedEarningsMember2021-12-310001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001551152us-gaap:NoncontrollingInterestMember2021-12-310001551152us-gaap:CommonStockMember2022-01-012022-09-300001551152us-gaap:TreasuryStockMember2022-01-012022-09-300001551152us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001551152us-gaap:RetainedEarningsMember2022-01-012022-09-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300001551152us-gaap:NoncontrollingInterestMember2022-01-012022-09-300001551152abbv:SyndesiMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310001551152abbv:SyndesiMembersrt:MaximumMemberus-gaap:CollaborativeArrangementMember2022-02-280001551152abbv:JuvisePharmaceuticalsMember2022-04-012022-06-300001551152abbv:JuvisePharmaceuticalsMemberus-gaap:OtherOperatingIncomeExpenseMember2022-04-012022-06-300001551152abbv:DJSAntibodiesLtdMembersrt:ScenarioForecastMemberus-gaap:SubsequentEventMember2022-10-012022-11-040001551152us-gaap:SubsequentEventMemberabbv:DJSAntibodiesLtdMembersrt:MaximumMember2022-11-040001551152abbv:CalicoLifeSciencesLLCMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300001551152abbv:TeneoOneMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300001551152abbv:TeneoOneMembersrt:MaximumMemberus-gaap:CollaborativeArrangementMember2021-09-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2022-09-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-30xbrli:pure0001551152abbv:JanssenBiotechIncMember2022-01-012022-09-300001551152abbv:JanssenBiotechIncMembercountry:USus-gaap:CollaborativeArrangementMember2022-07-012022-09-300001551152abbv:JanssenBiotechIncMembercountry:USus-gaap:CollaborativeArrangementMember2021-07-012021-09-300001551152abbv:JanssenBiotechIncMembercountry:USus-gaap:CollaborativeArrangementMember2022-01-012022-09-300001551152abbv:JanssenBiotechIncMembercountry:USus-gaap:CollaborativeArrangementMember2021-01-012021-09-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2021-12-310001551152abbv:GenentechInc.Member2022-01-012022-09-300001551152abbv:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300001551152abbv:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300001551152abbv:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300001551152abbv:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300001551152abbv:GenentechInc.Membercountry:USus-gaap:CollaborativeArrangementMember2022-07-012022-09-300001551152abbv:GenentechInc.Membercountry:USus-gaap:CollaborativeArrangementMember2021-07-012021-09-300001551152abbv:GenentechInc.Membercountry:USus-gaap:CollaborativeArrangementMember2022-01-012022-09-300001551152abbv:GenentechInc.Membercountry:USus-gaap:CollaborativeArrangementMember2021-01-012021-09-300001551152us-gaap:DevelopedTechnologyRightsMember2022-09-300001551152us-gaap:DevelopedTechnologyRightsMember2021-12-310001551152us-gaap:LicensingAgreementsMember2022-09-300001551152us-gaap:LicensingAgreementsMember2021-12-310001551152abbv:AllerganIntegrationPlanMember2022-09-300001551152abbv:AllerganIntegrationPlanMember2022-01-012022-09-300001551152us-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2022-07-012022-09-300001551152us-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2021-07-012021-09-300001551152us-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2022-01-012022-09-300001551152us-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2021-01-012021-09-300001551152us-gaap:CostOfSalesMemberabbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2022-07-012022-09-300001551152us-gaap:CostOfSalesMemberabbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2021-07-012021-09-300001551152us-gaap:CostOfSalesMemberabbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2022-01-012022-09-300001551152us-gaap:CostOfSalesMemberabbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2021-01-012021-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2022-07-012022-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2021-07-012021-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2022-01-012022-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2021-01-012021-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMemberabbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2022-07-012022-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMemberabbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2021-07-012021-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMemberabbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2022-01-012022-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMemberabbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2021-01-012021-09-300001551152us-gaap:EmployeeSeveranceMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberabbv:AllerganIntegrationPlanMember2022-07-012022-09-300001551152us-gaap:EmployeeSeveranceMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberabbv:AllerganIntegrationPlanMember2021-07-012021-09-300001551152us-gaap:EmployeeSeveranceMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberabbv:AllerganIntegrationPlanMember2022-01-012022-09-300001551152us-gaap:EmployeeSeveranceMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberabbv:AllerganIntegrationPlanMember2021-01-012021-09-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMemberabbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2022-07-012022-09-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMemberabbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2021-07-012021-09-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMemberabbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2022-01-012022-09-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMemberabbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2021-01-012021-09-300001551152us-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2022-07-012022-09-300001551152us-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2021-07-012021-09-300001551152us-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2022-01-012022-09-300001551152us-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2021-01-012021-09-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2022-07-012022-09-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2021-07-012021-09-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2022-01-012022-09-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2021-01-012021-09-300001551152us-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2021-12-310001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2021-12-310001551152us-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2022-09-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2022-09-300001551152abbv:OtherRestructuringPlansMember2022-07-012022-09-300001551152abbv:OtherRestructuringPlansMember2022-01-012022-09-300001551152abbv:OtherRestructuringPlansMember2021-07-012021-09-300001551152abbv:OtherRestructuringPlansMember2021-01-012021-09-300001551152abbv:OtherRestructuringPlansMember2021-12-310001551152abbv:OtherRestructuringPlansMember2022-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2022-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2021-12-310001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2022-01-012022-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMember2019-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2022-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2022-09-300001551152us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2021-12-310001551152us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-09-30iso4217:EUR0001551152us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-12-310001551152us-gaap:NetInvestmentHedgingMemberus-gaap:SeniorNotesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310001551152us-gaap:NetInvestmentHedgingMemberus-gaap:SeniorNotesMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-09-300001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-09-300001551152us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2022-09-300001551152us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2021-12-310001551152us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2022-09-300001551152us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2021-12-310001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherNoncurrentAssetsMember2022-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherNoncurrentAssetsMember2021-12-310001551152us-gaap:OtherLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2022-09-300001551152us-gaap:OtherLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2021-12-310001551152us-gaap:NetInvestmentHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-09-300001551152us-gaap:NetInvestmentHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-12-310001551152us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-09-300001551152us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-12-310001551152us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentAssetsMember2022-09-300001551152us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentAssetsMember2021-12-310001551152us-gaap:NetInvestmentHedgingMemberus-gaap:OtherLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-09-300001551152us-gaap:NetInvestmentHedgingMemberus-gaap:OtherLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-12-310001551152us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2022-09-300001551152us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2021-12-310001551152us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2022-09-300001551152us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2021-12-310001551152us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2022-09-300001551152us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2022-09-300001551152us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-09-300001551152us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-09-300001551152us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:InterestRateSwapMember2022-09-300001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:OtherLiabilitiesMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-09-300001551152us-gaap:OtherLiabilitiesMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-07-012022-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-07-012021-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-01-012021-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-07-012022-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-07-012021-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-01-012022-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-01-012021-09-300001551152us-gaap:CostOfSalesMember2022-09-300001551152us-gaap:InterestExpenseMember2022-09-300001551152us-gaap:SeniorNotesMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-07-012022-09-300001551152us-gaap:SeniorNotesMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-09-300001551152us-gaap:SeniorNotesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-012021-09-300001551152us-gaap:SeniorNotesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2022-07-012022-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2021-07-012021-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2021-01-012021-09-300001551152us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-09-300001551152us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-01-012021-09-300001551152us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-07-012022-09-300001551152us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-07-012021-09-300001551152us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2021-07-012021-09-300001551152us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-09-300001551152us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2022-07-012022-09-300001551152us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2021-01-012021-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMember2022-07-012022-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMember2021-07-012021-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMember2022-01-012022-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMember2021-01-012021-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2021-07-012021-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2022-01-012022-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2022-07-012022-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2021-01-012021-09-300001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-01-012021-09-300001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-01-012022-09-300001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-07-012022-09-300001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-07-012021-09-300001551152us-gaap:FairValueHedgingMemberus-gaap:InterestExpenseMember2022-07-012022-09-300001551152us-gaap:FairValueHedgingMemberus-gaap:InterestExpenseMember2021-07-012021-09-300001551152us-gaap:FairValueHedgingMemberus-gaap:InterestExpenseMember2022-01-012022-09-300001551152us-gaap:FairValueHedgingMemberus-gaap:InterestExpenseMember2021-01-012021-09-300001551152us-gaap:FairValueMeasurementsRecurringMember2022-09-300001551152us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001551152us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-09-300001551152us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-09-300001551152us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001551152us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001551152us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-09-300001551152us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-09-300001551152us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2022-09-300001551152us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001551152us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-09-300001551152us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-09-300001551152us-gaap:FairValueMeasurementsRecurringMember2021-12-310001551152us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001551152us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001551152us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001551152us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001551152us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001551152us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001551152us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001551152us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2021-12-310001551152us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001551152us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001551152us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001551152srt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember2022-09-300001551152srt:MaximumMemberus-gaap:MeasurementInputDiscountRateMember2022-09-300001551152srt:WeightedAverageMemberus-gaap:MeasurementInputDiscountRateMember2022-09-300001551152srt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember2021-12-310001551152srt:MaximumMemberus-gaap:MeasurementInputDiscountRateMember2021-12-310001551152srt:WeightedAverageMemberus-gaap:MeasurementInputDiscountRateMember2021-12-310001551152abbv:ProbabilityofPaymentforUnachievedMilestonesMembersrt:MinimumMember2022-09-300001551152abbv:ProbabilityofPaymentforUnachievedMilestonesMembersrt:MaximumMember2022-09-300001551152abbv:ProbabilityofPaymentforUnachievedMilestonesMembersrt:WeightedAverageMember2022-09-300001551152abbv:ProbabilityofPaymentforUnachievedMilestonesMembersrt:MinimumMember2021-12-310001551152abbv:ProbabilityofPaymentforUnachievedMilestonesMembersrt:MaximumMember2021-12-310001551152abbv:ProbabilityofPaymentforUnachievedMilestonesMembersrt:WeightedAverageMember2021-12-310001551152srt:MinimumMemberabbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember2022-09-300001551152abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMembersrt:MaximumMember2022-09-300001551152srt:WeightedAverageMemberabbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember2022-09-300001551152srt:MinimumMemberabbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember2021-12-310001551152abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMembersrt:MaximumMember2021-12-310001551152srt:WeightedAverageMemberabbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember2021-12-310001551152abbv:ProjectedYearofPaymentsMembersrt:MinimumMember2022-09-300001551152abbv:ProjectedYearofPaymentsMembersrt:MaximumMember2022-09-300001551152srt:WeightedAverageMemberabbv:ProjectedYearofPaymentsMember2022-09-300001551152abbv:ProjectedYearofPaymentsMembersrt:MinimumMember2021-12-310001551152abbv:ProjectedYearofPaymentsMembersrt:MaximumMember2021-12-310001551152srt:WeightedAverageMemberabbv:ProjectedYearofPaymentsMember2021-12-310001551152srt:MinimumMemberabbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember2021-12-310001551152srt:MinimumMemberabbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember2022-09-300001551152abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMembersrt:MaximumMember2022-09-300001551152abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMembersrt:MaximumMember2021-12-310001551152us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-09-300001551152us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-09-300001551152us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2022-09-300001551152us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2022-09-300001551152us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2022-09-300001551152us-gaap:FairValueInputsLevel1Member2022-09-300001551152us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001551152us-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001551152us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2021-12-310001551152us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2021-12-310001551152us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2021-12-310001551152us-gaap:FairValueInputsLevel1Member2021-12-310001551152us-gaap:AccountsReceivableMember2022-01-012022-09-30abbv:wholesaler0001551152us-gaap:AccountsReceivableMemberabbv:PrincipalUSCustomersMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-09-300001551152us-gaap:AccountsReceivableMemberabbv:PrincipalUSCustomersMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-12-310001551152abbv:HUMIRAMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-09-300001551152abbv:HUMIRAMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-09-300001551152abbv:SeniorNotesDue2022At3.450PercentMemberus-gaap:SeniorNotesMember2022-01-012022-01-310001551152abbv:SeniorNotesDue2022At3.450PercentMemberus-gaap:SeniorNotesMember2022-01-310001551152us-gaap:LoansPayableMemberabbv:FloatingRateTermLoanTrancheDueMay2025Member2022-02-280001551152us-gaap:LoansPayableMemberabbv:FloatingRateTermLoanTrancheDueMay2025Member2022-02-012022-02-280001551152us-gaap:LoansPayableMemberabbv:FloatingRateTermLoanTrancheDueMay2025RefinancedMember2022-02-280001551152us-gaap:SeniorNotesMemberabbv:SeniorNotesDue2022At3.250PercentMember2022-07-012022-07-310001551152us-gaap:SeniorNotesMemberabbv:SeniorNotesDue2022At3.250PercentMember2022-07-310001551152us-gaap:SeniorNotesMemberabbv:SeniorNotesDue2022At320PercentMember2022-09-012022-09-300001551152us-gaap:SeniorNotesMemberabbv:SeniorNotesDue2022At320PercentMember2022-09-300001551152abbv:SeniorNotes2.30PercentDue2021Memberus-gaap:SeniorNotesMember2021-04-012021-04-300001551152abbv:SeniorNotes2.30PercentDue2021Memberus-gaap:SeniorNotesMember2021-04-300001551152us-gaap:SeniorNotesMemberabbv:SeniorEuroNotesDue2021At0.500PercentMember2021-05-012021-05-310001551152us-gaap:SeniorNotesMemberabbv:SeniorEuroNotesDue2021At0.500PercentMember2021-05-310001551152us-gaap:SeniorNotesMemberabbv:SeniorNotesDueInMay2021AtFloatingRatesMember2021-05-012021-05-310001551152abbv:FloatingRateTermLoanTrancheDueMay2023Memberus-gaap:LoansPayableMember2021-09-300001551152abbv:FloatingRateTermLoanTrancheDueMay2023Memberus-gaap:LoansPayableMember2021-09-012021-09-300001551152abbv:FloatingRateTermLoanTrancheDueMay2023RefinancedMemberus-gaap:LoansPayableMember2021-09-300001551152abbv:SeniorNotesDue2021At5.000PercentMemberus-gaap:SeniorNotesMember2021-09-012021-09-300001551152abbv:SeniorNotesDue2021At5.000PercentMemberus-gaap:SeniorNotesMember2021-09-300001551152us-gaap:PensionPlansDefinedBenefitMember2022-07-012022-09-300001551152us-gaap:PensionPlansDefinedBenefitMember2021-07-012021-09-300001551152us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-09-300001551152us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-09-300001551152us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-07-012022-09-300001551152us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-012021-09-300001551152us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-09-300001551152us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-09-300001551152us-gaap:CostOfSalesMember2022-07-012022-09-300001551152us-gaap:CostOfSalesMember2021-07-012021-09-300001551152us-gaap:CostOfSalesMember2022-01-012022-09-300001551152us-gaap:CostOfSalesMember2021-01-012021-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300001551152us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001551152us-gaap:EmployeeStockOptionMember2022-09-300001551152abbv:RestrictedStockUnitsAndPerformanceSharesMember2022-01-012022-09-300001551152abbv:RestrictedStockUnitsAndPerformanceSharesMember2022-09-300001551152us-gaap:SubsequentEventMember2022-10-282022-10-2800015511522021-10-292021-10-2900015511522022-09-092022-09-0900015511522021-09-102021-09-1000015511522022-06-232022-06-2300015511522021-06-172021-06-1700015511522022-02-172022-02-1700015511522021-02-182021-02-180001551152abbv:December2018StockRepurchaseAuthorizationMember2022-01-012022-09-300001551152abbv:December2018StockRepurchaseAuthorizationMember2021-01-012021-09-300001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2021-12-310001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-12-310001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-09-300001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2022-01-012022-09-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-09-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-01-012022-09-300001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-09-300001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-09-300001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2022-09-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-09-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-09-300001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-09-300001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2020-12-310001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-12-310001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-09-300001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2021-01-012021-09-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-09-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-01-012021-09-300001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-09-300001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-09-300001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2021-09-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-09-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-09-300001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NetInvestmentHedgingMemberus-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2022-07-012022-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NetInvestmentHedgingMemberus-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2021-07-012021-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NetInvestmentHedgingMemberus-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2022-01-012022-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NetInvestmentHedgingMemberus-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2021-01-012021-09-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-07-012022-09-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-07-012021-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-07-012022-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-07-012021-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-01-012022-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-01-012021-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-07-012022-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-07-012021-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-01-012022-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-01-012021-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-07-012022-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-07-012021-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-01-012022-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-01-012021-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-07-012022-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-07-012021-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-01-012022-09-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-01-012021-09-300001551152abbv:NiaspanMember2022-01-012022-09-30abbv:lawsuitabbv:class_actionabbv:direct_purchaserabbv:end_payor_purchaser0001551152abbv:AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember2019-08-012019-08-31abbv:company0001551152abbv:HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember2019-03-012019-05-310001551152abbv:BystolicAntitrustLitigationMember2022-01-012022-09-300001551152abbv:PrescriptionDrugAbuseLitigationMember2022-09-30abbv:claim0001551152abbv:PrescriptionDrugAbuseLitigationInStateCourtsMember2022-09-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMemberabbv:PrescriptionDrugAbuseLitigationInStateCourtsMember2022-09-300001551152abbv:ElliottAssociatesL.P.Member2016-06-012016-06-30abbv:investment_fund0001551152abbv:ElliottAssociatesL.P.Member2022-02-012022-02-280001551152abbv:ElliottAssociatesL.P.Member2022-01-012022-01-310001551152abbv:ImmunologyMemberabbv:HUMIRAMembercountry:US2022-07-012022-09-300001551152abbv:ImmunologyMemberabbv:HUMIRAMembercountry:US2021-07-012021-09-300001551152abbv:ImmunologyMemberabbv:HUMIRAMembercountry:US2022-01-012022-09-300001551152abbv:ImmunologyMemberabbv:HUMIRAMembercountry:US2021-01-012021-09-300001551152abbv:ImmunologyMemberabbv:HUMIRAMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:ImmunologyMemberabbv:HUMIRAMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:ImmunologyMemberabbv:HUMIRAMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:ImmunologyMemberabbv:HUMIRAMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:ImmunologyMemberabbv:HUMIRAMember2022-07-012022-09-300001551152abbv:ImmunologyMemberabbv:HUMIRAMember2021-07-012021-09-300001551152abbv:ImmunologyMemberabbv:HUMIRAMember2022-01-012022-09-300001551152abbv:ImmunologyMemberabbv:HUMIRAMember2021-01-012021-09-300001551152abbv:ImmunologyMembercountry:USabbv:SKYRIZIMember2022-07-012022-09-300001551152abbv:ImmunologyMembercountry:USabbv:SKYRIZIMember2021-07-012021-09-300001551152abbv:ImmunologyMembercountry:USabbv:SKYRIZIMember2022-01-012022-09-300001551152abbv:ImmunologyMembercountry:USabbv:SKYRIZIMember2021-01-012021-09-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMember2022-07-012022-09-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMember2021-07-012021-09-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMember2022-01-012022-09-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMember2021-01-012021-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMembercountry:US2022-07-012022-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMembercountry:US2021-07-012021-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMembercountry:US2022-01-012022-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMembercountry:US2021-01-012021-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMember2022-07-012022-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMember2021-07-012021-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMember2022-01-012022-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMember2021-01-012021-09-300001551152abbv:ImbruvicaMemberabbv:HematologicOncologyMembercountry:US2022-07-012022-09-300001551152abbv:ImbruvicaMemberabbv:HematologicOncologyMembercountry:US2021-07-012021-09-300001551152abbv:ImbruvicaMemberabbv:HematologicOncologyMembercountry:US2022-01-012022-09-300001551152abbv:ImbruvicaMemberabbv:HematologicOncologyMembercountry:US2021-01-012021-09-300001551152abbv:ImbruvicaMemberabbv:HematologicOncologyMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:ImbruvicaMemberabbv:HematologicOncologyMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:ImbruvicaMemberabbv:HematologicOncologyMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:ImbruvicaMemberabbv:HematologicOncologyMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:ImbruvicaMemberabbv:HematologicOncologyMember2022-07-012022-09-300001551152abbv:ImbruvicaMemberabbv:HematologicOncologyMember2021-07-012021-09-300001551152abbv:ImbruvicaMemberabbv:HematologicOncologyMember2022-01-012022-09-300001551152abbv:ImbruvicaMemberabbv:HematologicOncologyMember2021-01-012021-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMembercountry:US2022-07-012022-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMembercountry:US2021-07-012021-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMembercountry:US2022-01-012022-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMembercountry:US2021-01-012021-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMember2022-07-012022-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMember2021-07-012021-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMember2022-01-012022-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMember2021-01-012021-09-300001551152abbv:BotoxCosmeticMemberabbv:AestheticsMembercountry:US2022-07-012022-09-300001551152abbv:BotoxCosmeticMemberabbv:AestheticsMembercountry:US2021-07-012021-09-300001551152abbv:BotoxCosmeticMemberabbv:AestheticsMembercountry:US2022-01-012022-09-300001551152abbv:BotoxCosmeticMemberabbv:AestheticsMembercountry:US2021-01-012021-09-300001551152abbv:BotoxCosmeticMemberabbv:AestheticsMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:BotoxCosmeticMemberabbv:AestheticsMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:BotoxCosmeticMemberabbv:AestheticsMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:BotoxCosmeticMemberabbv:AestheticsMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:BotoxCosmeticMemberabbv:AestheticsMember2022-07-012022-09-300001551152abbv:BotoxCosmeticMemberabbv:AestheticsMember2021-07-012021-09-300001551152abbv:BotoxCosmeticMemberabbv:AestheticsMember2022-01-012022-09-300001551152abbv:BotoxCosmeticMemberabbv:AestheticsMember2021-01-012021-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMembercountry:US2022-07-012022-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMembercountry:US2021-07-012021-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMembercountry:US2022-01-012022-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMembercountry:US2021-01-012021-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMember2022-07-012022-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMember2021-07-012021-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMember2022-01-012022-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMember2021-01-012021-09-300001551152abbv:OtherAestheticsMemberabbv:AestheticsMembercountry:US2022-07-012022-09-300001551152abbv:OtherAestheticsMemberabbv:AestheticsMembercountry:US2021-07-012021-09-300001551152abbv:OtherAestheticsMemberabbv:AestheticsMembercountry:US2022-01-012022-09-300001551152abbv:OtherAestheticsMemberabbv:AestheticsMembercountry:US2021-01-012021-09-300001551152abbv:OtherAestheticsMemberabbv:AestheticsMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:OtherAestheticsMemberabbv:AestheticsMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:OtherAestheticsMemberabbv:AestheticsMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:OtherAestheticsMemberabbv:AestheticsMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:OtherAestheticsMemberabbv:AestheticsMember2022-07-012022-09-300001551152abbv:OtherAestheticsMemberabbv:AestheticsMember2021-07-012021-09-300001551152abbv:OtherAestheticsMemberabbv:AestheticsMember2022-01-012022-09-300001551152abbv:OtherAestheticsMemberabbv:AestheticsMember2021-01-012021-09-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMembercountry:US2022-07-012022-09-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMembercountry:US2021-07-012021-09-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMembercountry:US2022-01-012022-09-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMembercountry:US2021-01-012021-09-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMember2022-07-012022-09-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMember2021-07-012021-09-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMember2022-01-012022-09-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMember2021-01-012021-09-300001551152abbv:VraylarMemberabbv:NeuroscienceMembercountry:US2022-07-012022-09-300001551152abbv:VraylarMemberabbv:NeuroscienceMembercountry:US2021-07-012021-09-300001551152abbv:VraylarMemberabbv:NeuroscienceMembercountry:US2022-01-012022-09-300001551152abbv:VraylarMemberabbv:NeuroscienceMembercountry:US2021-01-012021-09-300001551152abbv:DuodopaMemberabbv:NeuroscienceMembercountry:US2022-07-012022-09-300001551152abbv:DuodopaMemberabbv:NeuroscienceMembercountry:US2021-07-012021-09-300001551152abbv:DuodopaMemberabbv:NeuroscienceMembercountry:US2022-01-012022-09-300001551152abbv:DuodopaMemberabbv:NeuroscienceMembercountry:US2021-01-012021-09-300001551152abbv:DuodopaMemberabbv:NeuroscienceMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:DuodopaMemberabbv:NeuroscienceMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:DuodopaMemberabbv:NeuroscienceMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:DuodopaMemberabbv:NeuroscienceMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:DuodopaMemberabbv:NeuroscienceMember2022-07-012022-09-300001551152abbv:DuodopaMemberabbv:NeuroscienceMember2021-07-012021-09-300001551152abbv:DuodopaMemberabbv:NeuroscienceMember2022-01-012022-09-300001551152abbv:DuodopaMemberabbv:NeuroscienceMember2021-01-012021-09-300001551152abbv:UbrelvyMemberabbv:NeuroscienceMembercountry:US2022-07-012022-09-300001551152abbv:UbrelvyMemberabbv:NeuroscienceMembercountry:US2021-07-012021-09-300001551152abbv:UbrelvyMemberabbv:NeuroscienceMembercountry:US2022-01-012022-09-300001551152abbv:UbrelvyMemberabbv:NeuroscienceMembercountry:US2021-01-012021-09-300001551152abbv:NeuroscienceMembercountry:USabbv:QuliptaMember2022-07-012022-09-300001551152abbv:NeuroscienceMembercountry:USabbv:QuliptaMember2021-07-012021-09-300001551152abbv:NeuroscienceMembercountry:USabbv:QuliptaMember2022-01-012022-09-300001551152abbv:NeuroscienceMembercountry:USabbv:QuliptaMember2021-01-012021-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMembercountry:US2022-07-012022-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMembercountry:US2021-07-012021-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMembercountry:US2022-01-012022-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMembercountry:US2021-01-012021-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2022-07-012022-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2021-07-012021-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2022-01-012022-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2021-01-012021-09-300001551152abbv:EyeCareMembercountry:USabbv:LumiganGanfortMember2022-07-012022-09-300001551152abbv:EyeCareMembercountry:USabbv:LumiganGanfortMember2021-07-012021-09-300001551152abbv:EyeCareMembercountry:USabbv:LumiganGanfortMember2022-01-012022-09-300001551152abbv:EyeCareMembercountry:USabbv:LumiganGanfortMember2021-01-012021-09-300001551152abbv:EyeCareMemberabbv:LumiganGanfortMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:EyeCareMemberabbv:LumiganGanfortMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:EyeCareMemberabbv:LumiganGanfortMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:EyeCareMemberabbv:LumiganGanfortMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:EyeCareMemberabbv:LumiganGanfortMember2022-07-012022-09-300001551152abbv:EyeCareMemberabbv:LumiganGanfortMember2021-07-012021-09-300001551152abbv:EyeCareMemberabbv:LumiganGanfortMember2022-01-012022-09-300001551152abbv:EyeCareMemberabbv:LumiganGanfortMember2021-01-012021-09-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMembercountry:US2022-07-012022-09-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMembercountry:US2021-07-012021-09-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMembercountry:US2022-01-012022-09-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMembercountry:US2021-01-012021-09-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMember2022-07-012022-09-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMember2021-07-012021-09-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMember2022-01-012022-09-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMember2021-01-012021-09-300001551152abbv:EyeCareMembercountry:USabbv:RestasisMember2022-07-012022-09-300001551152abbv:EyeCareMembercountry:USabbv:RestasisMember2021-07-012021-09-300001551152abbv:EyeCareMembercountry:USabbv:RestasisMember2022-01-012022-09-300001551152abbv:EyeCareMembercountry:USabbv:RestasisMember2021-01-012021-09-300001551152abbv:EyeCareMemberus-gaap:NonUsMemberabbv:RestasisMember2022-07-012022-09-300001551152abbv:EyeCareMemberus-gaap:NonUsMemberabbv:RestasisMember2021-07-012021-09-300001551152abbv:EyeCareMemberus-gaap:NonUsMemberabbv:RestasisMember2022-01-012022-09-300001551152abbv:EyeCareMemberus-gaap:NonUsMemberabbv:RestasisMember2021-01-012021-09-300001551152abbv:EyeCareMemberabbv:RestasisMember2022-07-012022-09-300001551152abbv:EyeCareMemberabbv:RestasisMember2021-07-012021-09-300001551152abbv:EyeCareMemberabbv:RestasisMember2022-01-012022-09-300001551152abbv:EyeCareMemberabbv:RestasisMember2021-01-012021-09-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMembercountry:US2022-07-012022-09-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMembercountry:US2021-07-012021-09-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMembercountry:US2022-01-012022-09-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMembercountry:US2021-01-012021-09-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMember2022-07-012022-09-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMember2021-07-012021-09-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMember2022-01-012022-09-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMember2021-01-012021-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMembercountry:US2022-07-012022-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMembercountry:US2021-07-012021-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMembercountry:US2022-01-012022-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMembercountry:US2021-01-012021-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMember2022-07-012022-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMember2021-07-012021-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMember2022-01-012022-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMember2021-01-012021-09-300001551152abbv:OtherKeyProductsMemberabbv:CreonMembercountry:US2022-07-012022-09-300001551152abbv:OtherKeyProductsMemberabbv:CreonMembercountry:US2021-07-012021-09-300001551152abbv:OtherKeyProductsMemberabbv:CreonMembercountry:US2022-01-012022-09-300001551152abbv:OtherKeyProductsMemberabbv:CreonMembercountry:US2021-01-012021-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMembercountry:US2022-07-012022-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMembercountry:US2021-07-012021-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMembercountry:US2022-01-012022-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMembercountry:US2021-01-012021-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMemberus-gaap:NonUsMember2022-07-012022-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMemberus-gaap:NonUsMember2021-07-012021-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMemberus-gaap:NonUsMember2022-01-012022-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMemberus-gaap:NonUsMember2021-01-012021-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2022-07-012022-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2021-07-012021-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2022-01-012022-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2021-01-012021-09-300001551152abbv:OtherProductsMember2022-07-012022-09-300001551152abbv:OtherProductsMember2021-07-012021-09-300001551152abbv:OtherProductsMember2022-01-012022-09-300001551152abbv:OtherProductsMember2021-01-012021-09-30abbv:segment
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 001-35565
AbbVie Inc. | | | | | | | | |
(Exact name of registrant as specified in its charter) |
Delaware | | 32-0375147 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. employer identification number) |
1 North Waukegan Road
North Chicago, Illinois 60064-6400
Telephone: (847) 932-7900
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | |
Large Accelerated Filer | ☒ | Accelerated Filer | ☐ |
Non-Accelerated Filer | ☐ | Smaller reporting company | ☐ |
| | Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common Stock, par value $0.01 per share | | ABBV | | New York Stock Exchange |
| | | | Chicago Stock Exchange |
1.500% Senior Notes due 2023 | | ABBV23B | | New York Stock Exchange |
1.375% Senior Notes due 2024 | | ABBV24 | | New York Stock Exchange |
1.250% Senior Notes due 2024 | | ABBV24B | | New York Stock Exchange |
0.750% Senior Notes due 2027 | | ABBV27 | | New York Stock Exchange |
2.125% Senior Notes due 2028 | | ABBV28 | | New York Stock Exchange |
2.625% Senior Notes due 2028 | | ABBV28B | | New York Stock Exchange |
2.125% Senior Notes due 2029 | | ABBV29 | | New York Stock Exchange |
1.250% Senior Notes due 2031 | | ABBV31 | | New York Stock Exchange |
As of October 26, 2022, AbbVie Inc. had 1,768,480,508 shares of common stock at $0.01 par value outstanding.
AbbVie Inc. and Subsidiaries
Table of Contents
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings (unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, |
(in millions, except per share data) | | 2022 | | 2021 | | 2022 | | 2021 |
Net revenues | | $ | 14,812 | | | $ | 14,342 | | | $ | 42,933 | | | $ | 41,311 | |
| | | | | | | | |
Cost of products sold | | 5,022 | | | 4,390 | | | 13,244 | | | 13,126 | |
Selling, general and administrative | | 3,304 | | | 3,083 | | | 11,843 | | | 9,089 | |
Research and development | | 1,614 | | | 1,661 | | | 4,720 | | | 5,095 | |
Acquired IPR&D and milestones | | 40 | | | 402 | | | 454 | | | 719 | |
Other operating expense, net | | 229 | | | 500 | | | 57 | | | 432 | |
Total operating costs and expenses | | 10,209 | | | 10,036 | | | 30,318 | | | 28,461 | |
Operating earnings | | 4,603 | | | 4,306 | | | 12,615 | | | 12,850 | |
| | | | | | | | |
Interest expense, net | | 497 | | | 585 | | | 1,568 | | | 1,813 | |
Net foreign exchange loss | | 36 | | | 12 | | | 108 | | | 35 | |
Other expense (income), net | | (330) | | | 21 | | | 427 | | | 2,284 | |
Earnings before income tax expense | | 4,400 | | | 3,688 | | | 10,512 | | | 8,718 | |
Income tax expense | | 448 | | | 508 | | | 1,139 | | | 1,214 | |
Net earnings | | 3,952 | | | 3,180 | | | 9,373 | | | 7,504 | |
Net earnings attributable to noncontrolling interest | | 3 | | | 1 | | | 10 | | | 6 | |
Net earnings attributable to AbbVie Inc. | | $ | 3,949 | | | $ | 3,179 | | | $ | 9,363 | | | $ | 7,498 | |
| | | | | | | | |
Per share data | | | | | | | | |
Basic earnings per share attributable to AbbVie Inc. | | $ | 2.22 | | | $ | 1.78 | | | $ | 5.26 | | | $ | 4.21 | |
Diluted earnings per share attributable to AbbVie Inc. | | $ | 2.21 | | | $ | 1.78 | | | $ | 5.24 | | | $ | 4.19 | |
| | | | | | | | |
Weighted-average basic shares outstanding | | 1,771 | | | 1,770 | | | 1,771 | | | 1,769 | |
Weighted-average diluted shares outstanding | | 1,776 | | | 1,777 | | | 1,777 | | | 1,776 | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
| | | | | |
2022 Form 10-Q |  | 1 |
AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income (unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended September 30, | | Nine months ended September 30, |
(in millions) | 2022 | | 2021 | | 2022 | | 2021 |
Net earnings | $ | 3,952 | | | $ | 3,180 | | | $ | 9,373 | | | $ | 7,504 | |
| | | | | | | |
Foreign currency translation adjustments, net of tax expense (benefit) of $(11) for the three months and $(30) for the nine months ended September 30, 2022 and $(8) for the three months and $(32) for the nine months ended September 30, 2021 | (989) | | | (361) | | | (2,043) | | | (794) | |
Net investment hedging activities, net of tax expense (benefit) of $165 for the three months and $348 for the nine months ended September 30, 2022 and $51 for the three months and $123 for the nine months ended September 30, 2021 | 599 | | | 184 | | | 1,265 | | | 444 | |
Pension and post-employment benefits, net of tax expense (benefit) of $14 for the three months and $35 for the nine months ended September 30, 2022 and $17 for the three months and $50 for the nine months ended September 30, 2021 | 60 | | | 67 | | | 136 | | | 196 | |
| | | | | | | |
Cash flow hedging activities, net of tax expense (benefit) of $14 for the three months and $17 for the nine months ended September 30, 2022 and $13 for the three months and $16 for the nine months ended September 30, 2021 | 83 | | | 57 | | | 98 | | | 115 | |
Other comprehensive loss | (247) | | | (53) | | | (544) | | | (39) | |
Comprehensive income | 3,705 | | | 3,127 | | | 8,829 | | | 7,465 | |
Comprehensive income attributable to noncontrolling interest | 3 | | | 1 | | | 10 | | | 6 | |
Comprehensive income attributable to AbbVie Inc. | $ | 3,702 | | | $ | 3,126 | | | $ | 8,819 | | | $ | 7,459 | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
| | | | | |
2022 Form 10-Q |  | 2 |
AbbVie Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
| | | | | | | | | | | |
(in millions, except share data) | September 30, 2022 | | December 31, 2021 |
| (unaudited) | | |
Assets | | | |
Current assets | | | |
Cash and equivalents | $ | 11,832 | | | $ | 9,746 | |
Short-term investments | 47 | | | 84 | |
Accounts receivable, net | 10,743 | | | 9,977 | |
Inventories | 3,172 | | | 3,128 | |
Prepaid expenses and other | 4,570 | | | 4,993 | |
Total current assets | 30,364 | | | 27,928 | |
| | | |
Investments | 235 | | | 277 | |
Property and equipment, net | 4,893 | | | 5,110 | |
Intangible assets, net | 68,725 | | | 75,951 | |
Goodwill | 31,726 | | | 32,379 | |
Other assets | 5,382 | | | 4,884 | |
Total assets | $ | 141,325 | | | $ | 146,529 | |
| | | |
Liabilities and Equity | | | |
Current liabilities | | | |
Short-term borrowings | $ | 10 | | | $ | 14 | |
Current portion of long-term debt and finance lease obligations | 9,197 | | | 12,481 | |
Accounts payable and accrued liabilities | 23,505 | | | 22,699 | |
Total current liabilities | 32,712 | | | 35,194 | |
| | | |
Long-term debt and finance lease obligations | 60,399 | | | 64,189 | |
Deferred income taxes | 1,972 | | | 3,009 | |
Other long-term liabilities | 30,215 | | | 28,701 | |
| | | |
Commitments and contingencies | | | |
| | | |
Stockholders' equity | | | |
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,812,973,038 shares issued as of September 30, 2022 and 1,803,195,293 as of December 31, 2021 | 18 | | | 18 | |
Common stock held in treasury, at cost, 44,572,117 shares as of September 30, 2022 and 34,857,597 as of December 31, 2021 | (4,590) | | | (3,143) | |
Additional paid-in capital | 19,056 | | | 18,305 | |
Retained earnings | 4,953 | | | 3,127 | |
Accumulated other comprehensive loss | (3,443) | | | (2,899) | |
Total stockholders' equity | 15,994 | | | 15,408 | |
Noncontrolling interest | 33 | | | 28 | |
Total equity | 16,027 | | | 15,436 | |
| | | |
Total liabilities and equity | $ | 141,325 | | | $ | 146,529 | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
| | | | | |
2022 Form 10-Q |  | 3 |
AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Equity (unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
(in millions) | Common shares outstanding | | Common stock | | Treasury stock | | Additional paid-in capital | | Retained earnings | | Accumulated other comprehensive loss | | Noncontrolling interest | | Total |
Balance at June 30, 2021 | 1,767 | | | $ | 18 | | | $ | (3,022) | | | $ | 17,936 | | | $ | 740 | | | $ | (3,103) | | | $ | 25 | | | $ | 12,594 | |
| | | | | | | | | | | | | | | |
Net earnings attributable to AbbVie Inc. | — | | | — | | | — | | | — | | | 3,179 | | | — | | | — | | | 3,179 | |
Other comprehensive loss, net of tax | — | | | — | | | — | | | — | | | — | | | (53) | | | — | | | (53) | |
Dividends declared | — | | | — | | | — | | | — | | | (2,319) | | | — | | | — | | | (2,319) | |
| | | | | | | | | | | | | | | |
Purchases of treasury stock | — | | | — | | | (6) | | | — | | | — | | | — | | | — | | | (6) | |
Stock-based compensation plans and other | 1 | | | — | | | 8 | | | 172 | | | — | | | — | | | — | | | 180 | |
Change in noncontrolling interest | — | | | — | | | — | | | — | | | — | | | — | | | 2 | | | 2 | |
Balance at September 30, 2021 | 1,768 | | | $ | 18 | | | $ | (3,020) | | | $ | 18,108 | | | $ | 1,600 | | | $ | (3,156) | | | $ | 27 | | | $ | 13,577 | |
| | | | | | | | | | | | | | | |
Balance at June 30, 2022 | 1,768 | | | $ | 18 | | | $ | (4,591) | | | $ | 18,906 | | | $ | 3,516 | | | $ | (3,196) | | | $ | 35 | | | $ | 14,688 | |
Net earnings attributable to AbbVie Inc. | — | | | — | | | — | | | — | | | 3,949 | | | — | | | — | | | 3,949 | |
Other comprehensive loss, net of tax | — | | | — | | | — | | | — | | | — | | | (247) | | | — | | | (247) | |
Dividends declared | — | | | — | | | — | | | — | | | (2,512) | | | — | | | — | | | (2,512) | |
Purchases of treasury stock | — | | | — | | | (4) | | | — | | | — | | | — | | | — | | | (4) | |
Stock-based compensation plans and other | — | | | — | | | 5 | | | 150 | | | — | | | — | | | — | | | 155 | |
Change in noncontrolling interest | — | | | — | | | — | | | — | | | — | | | — | | | (2) | | | (2) | |
Balance at September 30, 2022 | 1,768 | | | $ | 18 | | | $ | (4,590) | | | $ | 19,056 | | | $ | 4,953 | | | $ | (3,443) | | | $ | 33 | | | $ | 16,027 | |
| | | | | | | | | | | | | | | |
Balance at December 31, 2020 | 1,765 | | | $ | 18 | | | $ | (2,264) | | | $ | 17,384 | | | $ | 1,055 | | | $ | (3,117) | | | $ | 21 | | | $ | 13,097 | |
| | | | | | | | | | | | | | | |
Net earnings attributable to AbbVie Inc. | — | | | — | | | — | | | — | | | 7,498 | | | — | | | — | | | 7,498 | |
Other comprehensive loss, net of tax | — | | | — | | | — | | | — | | | — | | | (39) | | | — | | | (39) | |
Dividends declared | — | | | — | | | — | | | — | | | (6,953) | | | — | | | — | | | (6,953) | |
| | | | | | | | | | | | | | | |
Purchases of treasury stock | (7) | | | — | | | (803) | | | — | | | — | | | — | | | — | | | (803) | |
Stock-based compensation plans and other | 10 | | | — | | | 47 | | | 724 | | | — | | | — | | | — | | | 771 | |
Change in noncontrolling interest | — | | | — | | | — | | | — | | | — | | | — | | | 6 | | | 6 | |
Balance at September 30, 2021 | 1,768 | | | $ | 18 | | | $ | (3,020) | | | $ | 18,108 | | | $ | 1,600 | | | $ | (3,156) | | | $ | 27 | | | $ | 13,577 | |
| | | | | | | | | | | | | | | |
Balance at December 31, 2021 | 1,768 | | | $ | 18 | | | $ | (3,143) | | | $ | 18,305 | | | $ | 3,127 | | | $ | (2,899) | | | $ | 28 | | | $ | 15,436 | |
Net earnings attributable to AbbVie Inc. | — | | | — | | | — | | | — | | | 9,363 | | | — | | | — | | | 9,363 | |
Other comprehensive loss, net of tax | — | | | — | | | — | | | — | | | — | | | (544) | | | — | | | (544) | |
Dividends declared | — | | | — | | | — | | | — | | | (7,537) | | | — | | | — | | | (7,537) | |
Purchases of treasury stock | (10) | | | — | | | (1,483) | | | — | | | — | | | — | | | — | | | (1,483) | |
Stock-based compensation plans and other | 10 | | | — | | | 36 | | | 751 | | | — | | | — | | | — | | | 787 | |
Change in noncontrolling interest | — | | | — | | | — | | | — | | | — | | | — | | | 5 | | | 5 | |
Balance at September 30, 2022 | 1,768 | | | $ | 18 | | | $ | (4,590) | | | $ | 19,056 | | | $ | 4,953 | | | $ | (3,443) | | | $ | 33 | | | $ | 16,027 | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
| | | | | |
2022 Form 10-Q |  | 4 |
AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (unaudited)
| | | | | | | | | | | |
| Nine months ended September 30, |
(in millions) (brackets denote cash outflows) | 2022 | | 2021 |
Cash flows from operating activities | | | |
Net earnings | $ | 9,373 | | | $ | 7,504 | |
Adjustments to reconcile net earnings to net cash from operating activities: | | | |
Depreciation | 582 | | | 630 | |
Amortization of intangible assets | 5,728 | | | 5,912 | |
Deferred income taxes | (1,415) | | | (153) | |
Change in fair value of contingent consideration liabilities | 647 | | | 2,447 | |
Stock-based compensation | 539 | | | 563 | |
Acquired IPR&D and milestones | 454 | | | 719 | |
Other charges related to collaborations | — | | | 500 | |
Gain on divestitures | (172) | | | (68) | |
Non-cash litigation reserve adjustments, net of cash payments | 2,261 | | | 21 | |
Impairment of intangible assets | 770 | | | 50 | |
Other, net | (151) | | | (185) | |
Changes in operating assets and liabilities, net of acquisitions: | | | |
Accounts receivable | (1,039) | | | (572) | |
Inventories | (516) | | | (30) | |
Prepaid expenses and other assets | (60) | | | (462) | |
Accounts payable and other liabilities | 330 | | | 1,454 | |
Income tax assets and liabilities, net | 184 | | | (628) | |
Cash flows from operating activities | 17,515 | | | 17,702 | |
| | | |
Cash flows from investing activities | | | |
| | | |
Acquisitions and investments | (494) | | | (837) | |
Acquisitions of property and equipment | (482) | | | (600) | |
Purchases of investment securities | (1,428) | | | (73) | |
Sales and maturities of investment securities | 1,460 | | | 88 | |
| | | |
|